Objectives: To assess the diagnostic value of tuberculosis-secreted Ag85B, ESAT-6 and CFP10 in pulmonary tuberculosis.

Method: Immunohistochemical (IHC) and acid-fast staining were performed, the detection efficiency of the two methods were analysed with chi-square test.

Results: Acid-fast staining demonstrated a sensitivity of (18/69, 26.09%) and a specificity of 100%. IHC staining for Ag85B, ESAT-6 and CFP10 was positive in all 18 cases with positive acid-fast staining and additionally positive in 25,36 and 30 cases, respectively, that were acid-fast-negative. The sensitivities of IHC staining for Ag85B, ESAT-6 and CFP10 were 62.32%, 78.26% and69.57%, respectively, while their specificities were 86.57%, 85.07% and 91.04%, respectively. Joint antigen analysis revealed that simultaneous positivity for two or three of Ag85B, ESAT-6 and CFP10 increased specificity (95.52% to 100%) but decreased sensitivity (49.28% to 62.31%). The presence of any one of the three antigens elevated sensitivity (81.16% to 88.41%) but lowered specificity (68.66% to 77.61%). Specificity reached 100% for concurrent positivity of all three antigens, while a sensitivity of 88.41% was observed for positivity of any one antigen.

Conclusions: Ag85B, ESAT-6, and CFP10 exhibits greater sensitivity in pulmonary tuberculosis and combined antigen testing enhances the diagnostic accuracy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541671PMC
http://dx.doi.org/10.1016/j.jctube.2024.100486DOI Listing

Publication Analysis

Top Keywords

ag85b esat-6
24
esat-6 cfp10
24
acid-fast staining
12
cfp10 pulmonary
8
pulmonary tuberculosis
8
ihc staining
8
staining ag85b
8
positivity three
8
three antigens
8
ag85b
6

Similar Publications

analysis for the development of multi-epitope vaccines against .

Front Immunol

December 2024

Korea National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Republic of Korea.

As Bacille Calmette-Guérin (BCG) vaccine's effectiveness is limited to only children, the development of new tuberculosis (TB) vaccines is being studied using several platforms, and a novel TB vaccine that overcomes this limitation is required. In this study, we designed an effective multi-epitope vaccine against using immunoinformatic analysis. First, we selected 11 highly antigenic proteins based on previous research: Ag85A, Ag85B, Ag85C, ESAT-6, MPT64, Rv2660c, TB10.

View Article and Find Full Text PDF

Objectives: To assess the diagnostic value of tuberculosis-secreted Ag85B, ESAT-6 and CFP10 in pulmonary tuberculosis.

Method: Immunohistochemical (IHC) and acid-fast staining were performed, the detection efficiency of the two methods were analysed with chi-square test.

Results: Acid-fast staining demonstrated a sensitivity of (18/69, 26.

View Article and Find Full Text PDF

A study of antigen selection by extracellular vesicles as vaccine candidates against infection.

J Med Microbiol

August 2024

Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, PR China.

Tuberculosis (TB), an infectious disease caused by (), remains a significant global public health concern. It is crucial to develop more effective vaccines for TB in order to achieve global control of the disease. Extracellular vesicles (EVs) are spherical membrane-bound structures released by pathogens and host cells.

View Article and Find Full Text PDF

Background: Current tuberculosis (TB) control strategies face limitations, such as low antibiotic treatment compliance and a rise in multidrug resistance. Furthermore, the lack of a safe and effective vaccine compounds these challenges. The limited efficacy of existing vaccines against TB underscores the urgency for innovative strategies, such as immunoinformatics.

View Article and Find Full Text PDF

Mucosal vaccines have the potential to elicit protective immune responses at the point of entry of respiratory pathogens, thus preventing even the initial seed infection. Unlike licensed injectable vaccines, mucosal vaccines comprising protein subunits are only in development. One of the primary challenges associated with mucosal vaccines has been identifying and characterizing safe yet effective mucosal adjuvants that can effectively prime multi-factorial mucosal immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!